PharmiWeb.com - Global Pharma News & Resources
28-Jun-2019

Immune Thrombocytopenia (ITP) Market size will reach worth around 2361.2 Million US$ with blooming CAGR of around 5.78% by 2023

Global Immune Thrombocytopenia (ITP) Market is projected to grow at blooming CAGR of around 5.78% over the forecast period and market size will reach worth around 2361.2 Million US$ in 2018-2023

The global immune thrombocytopenia (ITP) market studies the overall dynamics and trends of the market in terms of various segments and regional outlook for the period of 2017 to 2023. The report offers of historic and future market scenario in terms of market value, share and critical developments taking place in the industry. Market size, forecast, trends of each country and region are studied in the report for the focus period of 2017 to 2023.

We can provide sample pages for a better understanding of this report.
Request Sample of This Report @ http://www.amecoresearch.com/sample/11848

Qualitative assessment tools such as PEST analysis, cost structure analysis and regulatory compliance for pharmaceutical products are offered in the report. The report also comprises Pipeline Analysis which helps understand the comprehensive forecast scenario of the market in terms of value and dynamics. The report analyses the recent drug approval trends and market dynamics such as drivers, restrains, and opportunities, industry trends and future outlook in the global immune thrombocytopenia (ITP) market.

The report represents key players operating in the market along with its competitive landscape. The competitive landscape includes player positioning analysis, competitive matrix and market share analysis of the key players operating in the industry. The market attractive index highlights the most lucrative regional market to invest in the market.

The market is studied for regions such as North America (U.S., and Canada), Europe (U.K., Germany, France, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East amp; Africa (GCC, South Africa, and Rest of Middle East amp; Africa).

Key Takeaways:

What is the market size in 2017 and the growth rate of the global immune thrombocytopenia (ITP) market?

What is the market drivers, restrains, opportunities governing the global immune thrombocytopenia (ITP) market?

Which are the largest and the fastest growing segments in the global immune thrombocytopenia (ITP) market?

Who are the key players operating in the market and their market position?

What is the pipeline scenario, drug pricing analysis and technological development in the market?

View Detail Report With Complete Table Of Content@ http://www.amecoresearch.com/market-report/global-immune-thrombocytopenia-itp-market-mrfr-11848

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by improper clotting of blood. ITP can cause excessive bruising and bleeding owing to the unusually low levels of platelets or thrombocytes in the blood. ITP can occur in both children and adults. ITP can be classified as primary, i.e., occurring on its own, or secondary, occurring alongside another condition. Autoimmune diseases, chronic infections, medications, pregnancy, and certain cancers are common secondary triggers of ITP. The increasing prevalence of ITP is expected to contribute to the growth of the market over the forecast period.

The global immune thrombocytopenia (ITP) market has been segmented, by type, treatment, and end user.

Based on type, the global immune thrombocytopenia (ITP) market has been categorized as acute immune thrombocytopenia and chronic immune thrombocytopenia.

On the basis of treatment, the global immune thrombocytopenia (ITP) market is further sub-segmented into corticosteroids, thrombopoietin receptor agonists, and intravenous immunoglobulins (IVIG).

Based on end user, the market has been classified as hospitals and clinics, specialty centers, and research and academic institutes.
The global immune thrombocytopenia (ITP) market was valued at USD 1,670.9 million in 2017 and is expected to register a CAGR of 5.78% during the forecast period from 2018 to 2023.

Key Players

Some of the key players in the global immune thrombocytopenia (ITP) market are Amgen Inc., CSL Limited, Dova Pharmaceuticals, Jiangsu Hengrui Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd, Ligand Pharmaceuticals, Inc, Novartis AG, Rigel Pharmaceuticals, Inc, Shire, and Shionogi Inc.

Objectives of the Study

To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global immune thrombocytopenia (ITP) market
To provide insights into factors influencing and affecting market growth
To provide historical and forecast revenue of market segments and sub-segments with respect to countries
To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
To provide economic factors that influence the global immune thrombocytopenia (ITP) market
To provide a detailed analysis of the value chain and supply chain of the global immune thrombocytopenia (ITP) market

Target Audience

Research and Development (Ramp;D) Companies
Academic Institutes and Universities
Pharmaceutical Companies
Raw Material Suppliers
Suppliers and Distributors
Government
Potential Investors

Key Findings

The global immune thrombocytopenia (ITP) market is expected to reach USD 2,361.2 million by 2023 at a CAGR of 5.78% from 2018 to 2023
Based on type, the chronic immune thrombocytopenia segment holds the largest market share and is expected to reach USD 2,036.9 million by 2023 at a CAGR of 5.94% from 2018 to 2023
The market in the Americas is expected to account for the largest share of the global immune thrombocytopenia (ITP) market and is projected to reach USD 1,069.8 million by 2023
The immune thrombocytopenia (ITP) market in Asia-Pacific is projected to be the fastest-growing at a CAGR of 4.40% from 2018 to 2023

Regional Analysis

Americas
North America
US
Canada
Latin America

Europe
Western Europe
Germany
France
UK
Italy
Spain
Rest of Western Europe
Eastern Europe

Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific

Middle East amp; Africa
Middle East
Africa

Few Significant from Table Of Contents

Global Immune Thrombocytopenia (ITP) Market Research Report Forecast to 2023

1 Report Prologue

2 Executive Summary

3 Introduction
3.1 Definition
3.2 Scope of the Study
3.3 List of Assumptions
3.4 Market Structure

4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model

5 Market Dynamics
5.1 Overview
5.2 Drivers
5.2.1 Rising prevalence of Immune Thrombocytopenia (ITP)
5.2.2 Growing financial support by various private and government organizations
5.3 Restraints
5.3.1 Side effects of treatment options
5.3.2 High cost of IVIG treatment
5.4 Opportunities
5.4.1 Emerging therapies in immune thrombocytopenia

6 Market Factor Analysis
6.1 Value chain analysis
6.1.1 Ramp;D and Designing
6.1.2 Manufacturing
6.1.3 Distribution amp; Sales
6.1.4 Post-Sales Monitoring
6.2 Porterrsquo;s Five Forces Model
6.2.1 Bargaining Power of Suppliers
6.2.2 Bargaining Power of Buyers
6.2.3 Threat of New Entrants
6.2.4 Threat of Substitutes
6.2.5 Intense Rivalry

7 Global Immune Thrombocytopenia (ITP) Market by Type
7.1 Overview
7.2 Acute Immune Thrombocytopenia
7.3 Chronic Immune Thrombocytopenia

8 Global Immune Thrombocytopenia (ITP) Market by Treatment
8.1 Overview
8.2 Corticosteroids
8.3 Thrombopoietin receptor agonists
8.4 Intravenous Immunoglobulins (IVIG)

9 Global Immune Thrombocytopenia (ITP) Market by End-user
9.1 Overview
9.2 Hospital amp; Clinics
9.3 Specialty Centers
9.4 Research and Academic Institutes

10 Global Immune Thrombocytopenia (ITP) Market by Region
10.1 Overview
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 UK
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 South Korea
10.4.5 Australia
10.4.6 Rest of Asia-Pacific
10.5 Middle East amp; Africa
10.5.1 Middle East
10.5.2 Africa

11 Competitive Landscape
11.1 Overview
11.2 Company Share Analysis

12 Company Profiles
12.1 Amgen Inc.
12.1.1 Company Overview
12.1.2 Financial Overview
12.1.3 Products/Services Offered
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.1.6 Key Strategy
12.2 CSL Limited
12.2.1 Financial Overview
12.2.2 Products/Services Offered
12.2.3 Key Developments
12.2.4 SWOT Analysis
12.2.5 Key Strategy
12.3 Dova Pharmaceuticals
12.3.1 Company Overview
12.3.2 Financial Overview
12.3.3 Products/Services Offered
12.3.4 Key Developments
12.3.5 SWOT Analysis
12.3.6 Key Strategy
12.4 F. Hoffmann-La Roche Ltd
12.4.1 Company Overview
12.4.2 Financial Overview
12.4.3 Products/Services Offered
12.4.4 Key Developments
12.4.5 SWOT Analysis
12.4.6 Key Strategy
12.5 Jiangsu Hengrui Pharmaceutical Co., Ltd.
12.5.1 Company Overview
12.5.2 Financial Overview
12.5.3 Products/Services Offered
12.5.4 SWOT Analysis
12.5.5 Key Developments
12.5.6 Key strategy
12.6 Kyowa Hakko Kirin Co., Ltd.
12.6.1 Company Overview
12.6.2 Financial Overview
12.6.3 Products/Services Offered
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.6.6 Key Strategy
12.7 Ligand Pharmaceuticals, Inc.
12.7.1 Company Overview
12.7.2 Financial Overview
12.7.3 Products/Services Offered
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.7.6 Key Strategy
12.8 Novartis AG
12.8.1 Company Overview
12.8.2 Financial Overview
12.8.3 Products/Services Offered
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.8.6 Key Strategy
12.9 Rigel Pharmaceuticals, Inc.
12.9.1 Company Overview
12.9.2 Financial Overview
12.9.3 Products/Services Offered
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.9.6 Key Strategy
12.1 Shire
12.10.1 Company Overview
12.10.2 Financial Overview
12.10.3 Products/Services Offered
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.10.6 Key Strategy
12.11 Shionogi Inc.
12.11.1 Company Overview
12.11.2 Financial Overview
12.11.3 Products/Services Offered
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.11.6 Key Strategy

13 Appendix
13.1 Discussion Blue Print

Quick Buy This Premium Report From Here: http://www.amecoresearch.com/buy/11848

About Us:

Ameco Research is the one spot destination for all your research needs. Ameco Research holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making a purchase decision by understanding their requirements and suggesting best possible collection matching their needs.

Contact:

Email: sales@amecoresearch.com | +1 407 915 4157

Editor Details

Last Updated: 28-Jun-2019